The following should be read in conjunction with the consolidated financial statements, including the notes thereto, and Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on page 25.
As of or for the Fiscal Year Ended September 30,
(Amounts in thousands, except per share amounts)
2019(a)
2018(b)
2017(c)
2016(d)
2015(e)
Statement of Operations Data:
Revenue
$
179,589,121
$
167,939,635
$
153,143,826
$
146,849,686
$
135,961,803
Gross profit
5,138,312
4,612,317
4,546,002
4,272,606
3,529,313
Operating expenses
4,026,389
3,168,632
3,485,660
2,746,832
3,107,093
Operating income
1,111,923
1,443,685
1,060,342
1,525,774
422,220
Interest expense, net
157,769
174,699
145,185
139,912
109,036
Net income (loss)
854,135
1,615,892
364,484
1,427,929
(138,165
)
Net income (loss) attributable to AmerisourceBergen Corporation
$
855,365
$
1,658,405
$
364,484
$
1,427,929
$
(138,165
)
Earnings per share — diluted
$
4.04
$
7.53
$
1.64
$
6.32
$
(0.63
)
Cash dividends declared per common share
$
1.60
$
1.52
$
1.46
$
1.36
$
1.16
Weighted average common shares outstanding — diluted
211,840
220,336
221,602
225,959
217,786
Balance Sheet Data:
Cash and cash equivalents
$
3,374,194
$
2,492,516
$
2,435,115
$
2,741,832
$
2,167,442
Accounts receivable, net
12,386,879
11,314,226
10,303,324
9,175,876
8,222,951
Inventories
11,060,254
11,918,508
11,461,428
10,723,920
9,755,094
Property and equipment, net
1,770,516
1,892,424
1,797,945
1,530,682
1,192,510
Total assets
39,171,980
37,669,838
35,316,470
33,637,501
27,962,982
Accounts payable
28,385,074
26,836,873
25,404,042
23,926,320
20,886,439
Total debt
4,172,892
4,310,189
3,442,055
4,186,703
3,493,048
Total equity
2,993,206
3,049,961
2,064,461
2,129,404
616,386
Total liabilities and stockholders' equity
$
39,171,980
$
37,669,838
$
35,316,470
$
33,637,501
$
27,962,982
(a)
Includes a $421.3 million impairment of PharMEDium's long-lived assets, net of income tax benefit of $148.7 million; $245.8 million of employee severance, litigation, and other costs, net of income tax benefit of $84.6 million; a $107.8 million gain from antitrust litigation settlements, net of income tax expense of $38.1 million; $51.3 million of PharMEDium remediation costs, net of income tax benefit of $18.1 million; $16.7 million of LIFO credit, net of income tax expense of $5.9 million; a $16.3 million reversal of an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax expense of $5.7 million; and a $10.1 million gain on the sale of an equity investment, net of income tax expense of $3.6 million.
(b)
Includes $61.3 million of employee severance, litigation, and other costs, net of income tax benefit of $122.2 million; a $59.7 million goodwill impairment with no income tax benefit; $48.6 million of LIFO expense, net of income tax benefit of $18.7 million; $47.8 million of PharMEDium remediation costs, net of income tax benefit of $18.4 million; a $42.3 million loss on consolidation of equity investments with no income tax benefit; a $30.0 million impairment on a non-customer note receivable with no income tax benefit; a $25.9 million gain from antitrust litigation settlements, net of income tax expense of $10.0 million; a $17.2 million loss on early retirement of debt, net of income tax benefit of $6.6 million; and $15.9 million of expense for an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax benefit of $6.1 million.
(c)
Includes $101.1 million of LIFO credit, net of income tax expense of $56.7 million; a $0.9 million gain from antitrust litigation settlements, net of income tax expense of $0.5 million; and $937.4 million of employee severance, litigation, and other costs, net of income tax benefit of $21.9 million.
(d)
Includes $367.2 million of Warrants income, net of income tax benefit of $507.5 million; $120.9 million of LIFO expense, net of income tax benefit of $79.3 million; an $80.8 million gain from antitrust litigation settlements, net of income tax expense of $53.0 million; $62.1 million of employee severance, litigation, and other costs, net of income tax benefit of $40.8 million; and a $28.7 million pension settlement charge, net of income tax benefit of $18.9 million.
(e)
Includes $887.5 million of Warrants expense, net of income tax benefit of $25.3 million; $336.2 million of LIFO expense, net of income tax benefit of $206.6 million; a $40.6 million gain from antitrust litigation settlements, net of income tax expense of$24.9 million; a $30.6 million impairment charge on an equity investment, with no income tax benefit; and $23.5 million of employee severance, litigation, and other costs, net of income tax benefit of $14.4 million.
filings.tools